BASF receives licence for genome editing
The genome-editing tool CRISPR-Cas is one of the most groundbreaking developments for the field of molecular biotechnology throughout the last decades. Researchers worldwide are free to use this tool. However, the economical use is another matter: companies have to acquire licences from the institutes that patented the innovation.